Table 3 Changes in scores during three years of ChEI treatment in mild AD by APOE genotype
MMSE scorea | MMSE score, change from baselinea | MMSE score, improved/unchanged patients (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|
Number of non-carriers/ϵ4-carriersb | Non-carriers | ϵ4-carriers | P- value | Non-carriers | ϵ4-carriers | P-value | Non-carriers | ϵ4-carriers | P-value |
Baseline (n = 225/493) | 23.3 (23.0, 23.5) | 23.4 (23.2, 23.6) | 0.326 | ||||||
2 months (n = 213/469) | 24.0 (23.6, 24.4) | 24.0 (23.8, 24.3) | 0.843 | 0.64 (0.28, 1.00) | 0.60 (0.39, 0.80) | 0.834 | 73.2 | 72.7 | 0.926 |
6 months (n = 194/423) | 23.5 (23.0, 23.9) | 23.5 (23.2, 23.9) | 0.864 | 0.20 (−0.20, 0.59) | 0.17 (−0.12, 0.46) | 0.920 | 61.9 | 65.2 | 0.417 |
12 months (n = 178/388) | 22.7 (22.1, 23.3) | 22.9 (22.5, 23.3) | 0.597 | −0.53 (−1.10, 0.04) | −0.56 (−0.89, −0.22) | 0.945 | 56.2 | 54.4 | 0.716 |
18 months (n = 145/320) | 21.7 (20.9, 22.5) | 22.3 (21.9, 22.8) | 0.189 | −1.53 (−2.29, −0.78) | −1.18 (−1.57, −0.80) | 0.420 | 49.0 | 46.3 | 0.617 |
24 months (n = 130/292) | 21.0 (20.0, 22.0) | 21.5 (21.0, 22.1) | 0.361 | −2.52 (−3.45, −1.60) | −2.05 (−2.54, −1.57) | 0.377 | 44.6 | 40.8 | 0.522 |
30 months (n = 97/219) | 21.5 (20.5, 22.5) | 20.9 (20.2, 21.6) | 0.342 | −2.04 (−3.03, −1.05) | −2.74 (−3.36, −2.11) | 0.230 | 47.4 | 34.7 | 0.034 |
36 months (n = 91/199) | 21.0 (19.9, 22.2) | 20.3 (19.6, 21.1) | 0.325 | −2.81 (−3.83, −1.80) | −3.26 (−3.95, −2.57) | 0.471 | 35.2 | 31.7 | 0.591 |
ADAS-cog (0 to 70) score a | ADAS-cog (0 to 70) score, change from baseline a | ADAS-cog (0 to 70) score, improved/unchanged patients (%) | |||||||
Number of non-carriers/ϵ4-carriersb | Non-carriers | ϵ4-carriers | P-value | Non-carriers | ϵ4-carriers | P -value | Non-carriers | ϵ4-carriers | P -value |
Baseline (n = 220/488) | 17.8 (17.0, 18.6) | 17.1 (16.6, 17.7) | 0.220 | ||||||
6 months (n = 187/414) | 16.8 (15.9, 17.8) | 17.6 (16.8, 18.3) | 0.277 | 0.84 (0.09, 1.58) | −0.57 (−1.22, 0.08) | 0.011 | 63.0 | 51.5 | 0.010 |
12 months (n = 171/376) | 18.1 (16.8, 19.4) | 18.5 (17.6, 19.3) | 0.666 | 0.06 (−0.84, 0.96) | −1.78 (−2.50, −1.05) | 0.004 | 57.7 | 44.5 | 0.005 |
18 months (n = 137/306) | 19.4 (17.7, 21.1) | 19.5 (18.5, 20.5) | 0.893 | −1.88 (−3.30, −0.47) | −2.89 (−3.68, −2.11) | 0.185 | 48.1 | 38.8 | 0.075 |
24 months (n = 117/274) | 20.4 (18.2, 22.5) | 20.1 (18.9, 21.3) | 0.812 | −3.34 (−4.98, −1.70) | −4.07 (−4.96, −3.18) | 0.409 | 43.5 | 33.3 | 0.065 |
30 months (n = 92/203) | 20.7 (18.3, 23.1) | 21.7 (20.1, 23.3) | 0.526 | −3.71 (−5.85, −1.58) | −5.54 (−6.87, −4.22) | 0.139 | 42.2 | 28.7 | 0.031 |
36 months (n = 85/180) | 20.9 (18.2, 23.5) | 22.2 (20.3, 24.0) | 0.427 | −4.96 (−7.24, −2.68) | −6.78 (−8.28, −5.29) | 0.181 | 40.5 | 26.8 | 0.032 |
IADL score a | IADL score, change from baseline a | IADL score, improved/unchanged patients (%) | |||||||
Number of non-carriers/ϵ4-carriersb | Non-carriers | ϵ4-carriers | P -value | Non-carriers | ϵ4-carriers | P -value | Non-carriers | ϵ4-carriers | P -value |
Baseline (n = 219/481) | 15.3 (14.7, 16.0) | 14.3 (13.8, 14.7) | 0.010 | ||||||
6 months (n = 189/413) | 16.3 (15.6, 17.0) | 15.5 (15.0, 16.0) | 0.081 | −1.07 (−1.45, −0.69) | −1.14 (−1.41, −0.88) | 0.758 | 48.1 | 50.6 | 0.597 |
12 months (n = 175/379) | 17.6 (16.8, 18.4) | 16.8 (16.2, 17.4) | 0.123 | −2.31 (−2.80, −1.82) | −2.55 (−2.93, −2.16) | 0.482 | 34.3 | 34.8 | 0.923 |
18 months (n = 142/311) | 18.6 (17.6, 19.6) | 17.6 (16.9, 18.3) | 0.099 | −3.64 (−4.29, −2.99) | −3.63 (−4.09, −3.16) | 0.974 | 26.6 | 23.4 | 0.477 |
24 months (n = 128/283) | 19.8 (18.7, 20.9) | 18.4 (17.7, 19.1) | 0.029 | −5.13 (−5.96, −4.29) | −4.60 (−5.10, −4.10) | 0.268 | 18.4 | 17.9 | 0.889 |
30 months (n = 95/216) | 19.9 (18.7, 21.1) | 19.1 (18.3, 19.9) | 0.273 | −5.11 (−6.07, −4.15) | −5.71 (−6.34, −5.09) | 0.301 | 16.3 | 14.4 | 0.728 |
36 months (n = 91/191) | 20.3 (18.9, 21.7) | 19.7 (18.8, 20.6) | 0.500 | −6.23 (−7.31, −5.14) | −6.31 (−7.03, −5.60) | 0.895 | 17.0 | 12.1 | 0.266 |